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Abstract
Adeno-associated viral (AAV) manufacturing at scale continues to hinder the application of AAV technology to
gene therapy studies. Although scalable systems based on AAV–adenovirus, AAV–herpesvirus, and AAV–
baculovirus hybrids hold promise for clinical applications, they require time-consuming generation of reagents
and are not highly suited to intermediate-scale preclinical studies in large animals, in which several combina-
tions of serotype and genome may need to be tested. We observed that during production of many AAV
serotypes, large amounts of vector are found in the culture supernatant, a relatively pure source of vector in
comparison with cell-derived material. Here we describe a high-yielding, recombinant AAV production process
based on polyethylenimine (PEI)-mediated transfection of HEK293 cells and iodixanol gradient centrifugation of
concentrated culture supernatant. The entire process can be completed in 1 week and the steps involved are
universal for a number of different AAV serotypes. Process conditions have been optimized such that final
purified yields are routinely greater than 11014 genome copies per run, with capsid protein purity exceeding
90%. Initial experiments with vectors produced by the new process demonstrate equivalent or better trans-
duction both in vitro and in vivo when compared with small-scale, CsCl gradient-purified vectors. In addition,
the iodixanol gradient purification process described effectively separates infectious particles from empty cap-
sids, a desirable property for reducing toxicity and unwanted immune responses during preclinical studies.
Introduction
The use of recombinant adeno-associated viral (rAAV)vectors for clinical gene therapy applications has become
widespread and is largely due to the demonstration of long-
term transgene expression from rAAV vectors in animal
models with little associated toxicity and good overall safety
profiles in both preclinical and clinical trials (Snyder and
Flotte, 2002; Moss et al., 2004; Warrington and Herzog, 2006;
Maguire et al., 2008; Mueller and Flotte, 2008; Brantly et al.,
2009). Most early AAV gene therapy studies were performed
with serotype 2 vectors, but vector systems based on other
AAV serotypes with more efficient gene delivery and differ-
ent tissue specificity are currently in human trials and their
use will likely increase (Brantly et al., 2009; Neinhuis, 2009).
A major requirement for the development and eventual
marketing of a gene therapy drug is the ability to produce
the gene delivery vector at a sufficient scale. In the past this
requirement has been a barrier to the successful application
of rAAV vectors, but more recently several innovative pro-
duction systems have been developed that are compatible
with large-scale production for clinical application. These
new systems use adenovirus, herpesvirus, and baculovirus
hybrids to deliver the rAAV genome and trans-acting helper
functions to producer cells and have been reviewed (Clement
et al., 2009; Virag et al., 2009; Zhang et al., 2009). The ease of
introduction of the required genetic elements to the producer
cell line through rAAV hybrid virus infection permits effi-
cient rAAV vector production and, importantly, up-scaling
of the process to bioreactors. These systems are particularly
suited to final clinical candidate vectors but because of the
need to make the hybrid viruses for each vector, they are less
suited to early development and preclinical studies in which
several combinations of transgene and vector serotype may
need to be evaluated.
Although much preclinical rAAV-based gene therapy
work has been performed in mice, results obtained in
larger animals are often considered more predictive of actual
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clinical outcomes. Large animal studies require higher rAAV
vector doses and, to satisfy these demands, a versatile pro-
duction system that can rapidly produce a variety of test
vectors at scale without the need for time-consuming pro-
duction of intermediates is required. Transient transfection
by calcium phosphate coprecipitation of plasmid DNAs
containing the AAV vector genome, the AAV capsid gene,
and the trans-acting helper genes into HEK293 cells (a pro-
cess known as ‘‘triple transfection’’) has long been the stan-
dard method to produce rAAV in the research laboratory
(Grimm et al., 1998; Matsushita et al., 1998; Salvetti et al.,
1998; Xiao et al., 1998). Transfection-based methods remain
the most versatile of all rAAV production techniques and
permit simultaneous manufacture of different rAAV vectors.
However, calcium phosphate triple transfection has gener-
ally not been considered ideal for large-scale rAAV pro-
duction because of a lack of compatibility with suspension
culture systems. Polyethylenimine (PEI) has been used as a
transfection reagent to produce AAV vectors for some time
(Grieger et al., 2006; Reed et al., 2006), but some promising
results using this reagent have demonstrated the production
of rAAV2 vectors in mammalian cell suspension culture with
unpurified yields of 1–31013 vector particles per liter, which
are comparable to yields from attached-mode transfection
systems (Durocher et al., 2007; Hildinger et al., 2007). The
advantages of PEI-based transfection are that it can also be
performed in serum-free medium without the need for the
medium exchanges that are typically required with conven-
tional calcium phosphate-mediated transfection (Durocher
et al., 2007). These features translate into lower cost and the
elimination of concerns surrounding animal-derived serum
such as the presence of prions and other adventitious agents.
A further impediment to the scale-up of rAAV vector
production occurs during downstream processing of the
vector. At small scale, the most prevalent method used for
rAAV vector purification involves multiple rounds of over-
night cesium chloride gradient centrifugation (Zolotukhin
et al., 1999). This purification method can be performed easily
with standard laboratory equipment, is generally high-
yielding, and when performed carefully gives vector of rea-
sonable purity. The drawbacks of this technique, however,
are first that prolonged exposure to CsCl has been reported
to compromise the potency of rAAV vectors (Zolotukhin
et al., 1999; Auricchio et al., 2001; Brument et al., 2002) and
second that the gradients have a limited loading capacity for
cell lysate, which can in turn limit rAAV purification scale-
up. An alternative gradient medium, iodixanol, has also been
used to purify rAAV vectors (Hermens et al., 1999; Zolotu-
khin et al., 1999). This isotonic medium was developed
originally as a contrast agent for use during coronary angi-
ography and the low associated toxicity and relative inert-
ness are advantages over cesium chloride from both safety
and vector potency points of view (Zolotukhin et al., 1999).
However, iodixanol shares the same drawback as cesium
chloride in that the loading capacity for rAAV production
culture cell lysate and thus the scalability of rAAV purifi-
cation are limited. To overcome these gradient-specific con-
straints, researchers have gravitated toward ion-exchange
chromatography and more recently affinity purification us-
ing single-domain heavy chain antibody fragments to purify
AAV at scale (Auricchio et al., 2001; Brument et al., 2002;
Kaludov et al., 2002; Zolotukhin et al., 2002; Davidoff et al.,
2004; Smith et al., 2009). Using these techniques, yields,
scalability, and purity are all enhanced. However, there re-
main vector-related impurities such as empty capsids, which
are not generally separated from fully functional vector
particles by chromatography-based techniques. Although
some progress has been made with AAV2 vectors to develop
ion-exchange-based resolution of empty and full vector
particles (Qu et al., 2007; Okada et al., 2009), CsCl gradient
centrifugation remains the best characterized method for
removing empty particles from rAAV vector preparations.
We observed that in contrast to AAV2, most other AAV
serotypes were released primarily into the medium of cal-
cium phosphate-transfected production cultures and not re-
tained in the cell lysate (Vandenberghe et al., 2010). This
observation confirms a similar finding reported for AAV8
(Okada et al., 2009). Because this distribution occurs in the
absence of cell lysis, we reasoned that the production culture
medium would represent a relatively pure source of rAAV
vector and that the lower level of cellular contaminants may
improve the loading capacity and resolution of purification
gradients. Here we describe a scaled rAAV production
method suitable for large animal studies, which is based on
PEI transfection and supernatant harvest. The method is
high-yielding, versatile for the production of vectors with
different serotypes and transgenes, and simple enough that it
may be performed in most laboratories with a minimum of
specialized techniques and equipment. In addition, we
demonstrate the use of iodixanol gradients for the separation
of genome-containing vectors from empty particles.
Materials and Methods
Cell culture
Late-passage HEK293 cell cultures were maintained on
15-cm plates in Dulbecco’s modified Eagle’s medium
(DMEM; Mediatech, Manassas, VA) with the addition 10%
fetal bovine serum (FBS; HyClone Laboratories, South
Logan, UT). The cells were passaged twice weekly to main-
tain them in exponential growth phase. For small-scale
transfections 1106 HEK293 cells were seeded per well of
6-well plates and 1.5107 cells were seeded into 15-cm dishes.
For large-scale production HEK293 cells from 16 confluent
15-cm plates were split into two 10-layer cell stacks (Corning,
Corning, NY) containing 1 liter of DMEM–10% FBS 4 days
before transfection. The day before transfection, the two cell
stacks were trypsinized and the cells were resuspended in
200 ml of medium. Cell clumps were allowed to settle before
plating 6.3108 cells into each of six cell stacks. The cells were
allowed to attach for 24 hr before transfection. Confluency
of the cell stacks was monitored with a Diaphot inverted
microscope (Nikon, Melville, NY) from which the phase-
contrast hardware had been removed in order to accommo-
date the cell stack on the microscope stage.
Plasmids
The plasmids used for all transfections were as follows: (1)
cis plasmid pENNAAVCMVeGFP.RBG containing an en-
hanced green fluorescent protein (eGFP) expression cassette
flanked by AAV2 inverted terminal repeats (ITRs); (2) trans
plasmids pAAV2/1, pAAV2/6, pAAV2/7, pAAV2/8, and
pAAV2/9 containing the AAV2 rep gene and capsid protein
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genes from AAV1, 6, 7, 8, and 9, respectively; and (3) ade-
novirus helper plasmid pAdDF6. Fifteen- to 50-mg lots of
>90% supercoiled plasmid were obtained (Puresyn, Mal-
vern, PA) and used for all transfections.
Calcium phosphate transfection
Small-scale calcium phosphate transfections were per-
formed by triple transfection of AAV cis, AAV trans, and
adenovirus helper plasmids as previously described (Gao et al.,
2002). Briefly, the medium on 85–90% confluent HEK293
monolayers in 6-well plates was changed to DMEM–10% FBS
2 hr before transfection. Plasmids at a ratio of 2:1:1 (1.73mg of
adenovirus helper plasmid/0.86mg of cis plasmid/0.86mg of
trans plasmid per well) were calcium phosphate precipitated
and added dropwise to plates. Transfections were incubated
at 378C for 24 hr, at which point the medium was changed
again to DMEM–10% FBS. The cultures were further incu-
bated to 72 hr postinfection before harvesting the cells and
medium separately. For large-scale transfection of cell stacks
the plasmid ratio was kept constant but all reagent amounts
were increased by a factor of 630. The transfection mix was
added directly to 1 liter of DMEM–10% FBS and this mixture
was used to replace the medium in the cell stack. The medium
was changed at 24 hr posttransfection. Cells and medium
were harvested 72 or 120 hr posttransfection either directly or
after further incubation for 2 hr in the presence of 500 mM
NaCl. When vector present in the cells was to be quantified,
the cells were released by trypsinization and lysates were
formed by three freeze–thaw cycles.
Small-scale vector preparation
Forty 15-cm plates were transfected by the calcium
phosphate method and cell lysates were prepared 72 hr
posttransfection with three successive freeze–thaw cycles
(–808C/378C). Cell lysates were purified by two rounds of
cesium chloride centrifugation and pure gradient fractions
were concentrated and desalted, using Amicon Ultra-15
centrifugal concentrator devices (Millipore, Bedford, MA).
Small-scale polyethylenimine transfection
For polyethylenimine (PEI)-based triple transfections of
HEK293 cells in six-well plates the same plasmid amounts
were used as described for calcium phosphate transfections.
PEI ‘‘Max’’ (Polysciences, Warrington, PA) was dissolved at
1 mg/ml in water and the pH was adjusted to 7.1. Two mi-
crograms of PEI was used per microgram of DNA trans-
fected. PEI and DNA were each added to 100 ml of serum-free
DMEM and the two solutions were combined and mixed by
vortexing. After 15 min of incubation at room temperature
the mixture was added to 1.2 ml of serum-free medium and
used to replace the medium in the well. No further medium
change was carried out. For 15-cm plate the plasmid ratio
was kept constant but the amounts of plasmid and other
reagents used were increased by factors of 15.
Large-scale polyethylenimine transfection
Large-scale PEI-based transfections were performed in
10-layer cell stacks containing 75% confluent monolayers of
HEK293 cells. Plasmids at a ratio of 2:1:1 (1092mg of ade-
novirus helper plasmid/546 mg of cis plasmid/546 mg of trans
plasmid per cell stack) were used. The PEI ‘‘Max’’/DNA ratio
was maintained at 2:1 (w/w). For each cell stack, the plasmid
mix and PEI were each added to a separate tube containing
serum-free DMEM (total volume, 54 ml). The tubes were
mixed by vortexing and incubated for 15 min at room tem-
perature, after which the mixture was added to 1 liter of
serum-free DMEM containing antibiotics. The culture me-
dium in the stack was decanted and replaced with the
DMEM–PEI–DNA mix, and the stack was incubated in a
standard 5% CO2, 378C incubator. At 72 hr posttransfection
500 ml of fresh serum-free DMEM was added and the incu-
bation was continued to 120 hr posttransfection. At this
point, Benzonase (EMD Chemicals, Gibbstown, NJ) was
added to the culture supernatant to a final concentration of
25 units/ml and the stack was reincubated for 2 hr. NaCl was
added to 500 mM and the incubation was resumed for an
additional 2 hr before harvest of the culture medium (at this
point the culture medium was called the downstream feed-
stock). When cell-associated vector was to be quantified, the
cells were released by trypsinization and lysates were formed
by three sequential freeze–thaw cycles (808C/378C).
Downstream processing
Ten liters of feedstock culture medium from six cell stacks
was clarified through a 0.5-mm Profile II depth filter (Pall, Fort
Washington, NY) into a 10-liter Allegro medium bag (Pall).
The clarified feedstock was then concentrated by tangential
flow filtration (TFF), using a NovaSet-LS LHV holder with
customized 0.25-inch (inner diameter) tubing and ports
(TangenX Technology, Shrewsbury, MA) and a 0.1-m2 Sius-LS
single-use TFF screen channel cassette with a 100-kDa mo-
lecular weight cutoff (MWCO) HyStream membrane (Tan-
genX Technology). A 125-fold concentration to 85 ml was
performed according to the manufacturer’s recommendations
with a transmembrane pressure of 10–12 psi maintained
throughout the procedure. The TFF filter was discarded after
each run and the system was sanitized with 0.2 N NaOH
between runs. The concentrated feedstock was reclarified by
centrifugation at 10,500g and 158C for 20 min and the su-
pernatant was carefully removed to a new tube. Six iodixanol
step gradients were formed according to the method of
Zolotukhin and colleagues (1999) with some modifications
as follows: Increasingly dense iodixanol (OptiPrep; Sigma-
Aldrich, St Louis, MO) solutions in phosphate-buffered saline
(PBS) containing10 mM magnesium chloride and 25 mM po-
tassium were successively underlaid in 40 ml of Quick-Seal
centrifuge tubes (Beckman Instruments, Palo Alto, CA). The
steps of the gradient were 4 ml of 15%, 9 ml of 25%, 9 ml of
40%, and 5 ml of 54% iodixanol. Fourteen milliliters of the
clarified feedstock was then overlaid onto the gradient and the
tube was sealed. The tubes were centrifuged for 70 min at
350,000g in a 70Ti rotor (Beckman Instruments) at 188C and
the gradients were fractionated through an 18-gauge needle
inserted horizontally approximately 1 cm from the bottom of
the tube. Fractions were diluted 20-fold with water into an
ultraviolet (UV)-transparent 96-well plate (Corning) and the
absorbance was measured at 340 nm. A spike in OD340 (op-
tical density at 340 nm) readings indicated the presence of the
major contaminating protein band and all fractions below this
spike were collected and pooled. Pooled fractions from all six
gradients were combined, diafiltered against 10 volumes of
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the final formulation buffer (PBS–35 mM NaCl), and concen-
trated 4-fold to *10 ml by tangential flow filtration according
to the manufacturer’s instructions, using a 0.01-m2 single-use
Sius TFF cassette with a 100-kDa MWCO HyStream screen
channel membrane (TangenX Technology) and an LV Cen-
tramate cassette holder (Pall). A transmembrane pressure of
10 psi was maintained throughout the process. The holdup
volume of the apparatus was kept low, using minimal lengths
of platinum-cured silicone tubing (inner diameter, 1.66 mm)
(Masterflex; Cole Parmer Instrument, Vernon Hills, IL). In
addition, all wettable parts were pretreated for 2 hr with 0.1%
Pluronic F-68 (Invitrogen, Carlsbad, CA) in order to minimize
binding of the vector to surfaces. The TFF filter was discarded
after each run and the system was sanitized with 0.2 N NaOH
between runs. Glycerol was added to the diafiltered, concen-
trated product to a final concentration of 5% and the prepa-
ration was aliquoted and stored at –808C.
Vector characterization
DNase I-resistant vector genomes were titered by TaqMan
PCR amplification (Applied Biosystems, Foster City, CA),
using primers and probes directed against the polyadenyla-
tion signal encoded in the transgene cassette. The purity of
gradient fractions and final vector lots were evaluated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) and the proteins were visualized by SYPRO
ruby staining (Invitrogen) and UV excitation. Purity relative to
nonvector impurities visible on stained gels was determined
with GeneTools software (Syngene, Frederick, MD). The
empty particle content of vector preparations was assessed by
negative staining and electron microscopy. Copper grids (400-
mesh, coated with a Formvar/thin carbon film; Electron Mi-
croscopy Sciences, Hatfield, PA) were pretreated with 1% al-
cian blue (Electron Microscopy Sciences) and loaded with 5ml
of vector preparation. The grids were then washed, stained
with 1% uranyl acetate (Electron Microscopy Sciences), and
viewed with a Philips CM100 transmission electron micro-
scope. Ratios of empty to full particles were determined by
direct counting of the electron micrographs.
Relative vector potency assessment
Early-passage HEK293 cells were plated to 80% confluency
in 96-well plates and infected with AAV vector at a multiplic-
ity of infection (MOI) of 10,000 in the presence of wild-type
adenovirus type 5 (MOI, 400). Forty-eight hours postinfection
GFP fluorescence images were captured digitally and the
fluorescence intensity was quantified as described previously
(Wang et al., 2010), using ImageJ software (Ferreira and
Rasband, 2010). For in vivo analysis of transduction, C57BL/6
mice were injected intravenously with 11011 genome copies
of AAV vector. The animals were necropsied 9 days postin-
jection, the livers were sectioned and imaged for GFP fluo-
rescence as described previously (Wang et al., 2010), and
fluorescence intensity was quantified with ImageJ software.
Results
Comparison of transfection reagents
for rAAV production
The standard upstream method for producing rAAV vec-
tors at small scale in our laboratory (total yield, *1–21013
genome copies [GC]) is based on calcium phosphate-mediated
triple transfection of HEK293 cells in forty 15-cm tissue culture
plates. Although this method reproducibly yields vectors of
various AAV serotypes with good titers in both the cell pellet
and the culture medium (Vandenberghe et al., 2010), it is
technically cumbersome, requires the presence of animal se-
rum, and involves two medium changes. For scaled rAAV
production we reasoned that a less complicated, more robust
transfection agent such as polyethylenimine (PEI) would be
required. The production of rAAV7 vector carrying an eGFP
expression cassette (rAAV7-eGFP) after either calcium phos-
phate- or PEI-mediated triple transfection, was quantified by
quantitative PCR (qPCR) of DNase-resistant vector genomes
in both cells and media of six-well plate HEK293 production
cultures (Fig. 1a). With either transfection method, rAAV7-
eGFP production was found to partition equally between the
cells and culture medium at similar levels, despite stronger
expression of the eGFP transgene in the calcium phosphate-
transfected cells. The results indicate that, interestingly,
transgene expression levels in the production culture are not
predictive of rAAV production yields but more importantly
that rAAV7-eGFP is released to the culture medium at similar
levels irrespective of the transfection technique.
Effect of serotype and salt addition on rAAV release
to the culture medium
Having established the release of rAAV7-eGFP to the
culture medium after PEI triple transfection, an immediate
FIG. 1. Comparison of transfection agents for rAAV7 pro-
ductivity and release to the culture medium. (a) Six-well
plates were seeded with HEK293 cells and transfected with
three plasmids carrying the vector genome, AAV2 rep/
AAV7 cap genes, and adenovirus helper functions, respec-
tively, using polyethylenimine (PEI) or calcium phosphate as
the transfection reagent. DNase-resistant vector genome
copies (GC) present in cell lysates and the production culture
medium at 72 hr posttransfection were quantified by qPCR.
(b) Ten-layer Corning cell stacks containing HEK293 cells
were triple transfected by both PEI and calcium phosphate
methods and vector genome copies in the culture superna-
tant and cells were determined 120 hr later.
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goal was to demonstrate similar release with other AAV
serotypes. In addition, we were interested to determine
whether we could manipulate the 45% of detectable vector
that remained associated with the cells (Fig. 1a) into the
culture medium. It was found that by simply postponing
the harvest until 120 hr after PEI transfection, as opposed to
the standard 72 hr, the total vector in the culture medium
could be doubled (data not shown). Adopting this strategy,
15-cm plates of HEK293 cells were triple transfected with
PEI. Trans plasmids encoding five different AAV serotype
capsid genes were included in the various transfection mixes
and after a 120-hr incubation the culture medium and cells
were harvested either immediately, or 2 hr after addition of
500 mM NaCl. The encapsidated AAV genomes in the cell
lysates and culture medium were then quantified by qPCR
(Fig. 2). Each of the five AAV serotypes tested could be re-
leased to the supernatant after 5 days of incubation without
salt addition at levels between 61.5 and 86.3% of the total GC
yield. This result confirmed our observation during early
development runs that increased incubation time post-
transfection led to higher titers of AAV vector in the culture
medium. Incubation of production cultures with salt has
been demonstrated to cause release of AAV2 to the super-
natant presumably through a mechanism mediated by cel-
lular stress (Atkinson et al., 2005). The high-salt incubation
performed here led to a further *20% GC release of AAV6
and AAV9 vectors to the culture medium, but elicited little
change with the other serotypes.
Effect of scale-up on rAAV7 vector yields
The major goal at the outset of this work was to develop a
scaled AAV production system that could be performed in
most laboratories using standard equipment to support large
animal preclinical studies. Hence we chose Corning 10-layer
cell stacks to scale up the PEI-based transfection because this
type of tissue culture vessel can be accommodated by stan-
dard laboratory incubators. Initially a single 10-layer cell
stack was seeded with 6.3108 HEK293 cells such that the
monolayers would be 75% confluent the next day. To assess
the confluency of the bottom HEK293 monolayer before
transfection, a standard laboratory microscope was adapted
by removing the phase-contrast hardware such that the cell
stacks could be accommodated. One cell stack was triple
transfected with the relevant plasmids to produce AAV7-
eGFP vector, using either calcium phosphate or PEI (see
Materials and Methods), and then incubated to 120 hr post-
infection before quantification of DNase-resistant vector ge-
nomes in both cells and medium (Fig. 1b). Per-cell yields
from the PEI-transfected cell stack were similar to those ob-
tained previously in 6-well and 15-cm plates (Fig. 1a and Fig.
2). The overall yield from the culture medium in this ex-
periment was 2.21013 GC per cell stack. The calcium
phosphate-transfected stack produced significantly lower
vector yields per cell than was observed previously in plates
and this effect may result from a lack of diffusion of CO2 into
the central areas of the cell stack. On the basis of the 10-layer
cell stack transfection results, PEI was chosen as the trans-
fection reagent for further development of the scaled proce-
dure.
Downstream processing of rAAV7-eGFP production
culture medium
A primary goal in developing the scaled production pro-
cess was to maintain flexibility such that any AAV vector
could be purified by a generic method. Separation of vector
from contaminants on the basis of density and size can be
applied to multiple vector serotypes. Hence we chose to
concentrate the rAAV7 vector in the culture medium by
tangential flow filtration (TFF) to volumes small enough to
permit purification over iodixanol density gradients. Pre-
clarification of the production culture medium through a 0.5-
mm depth filter was necessary to remove cellular debris and
detached cells and to prevent clogging of the TFF membrane.
A 130-fold concentration was then achieved with a disposable,
100-kDa cutoff, screen channel TFF membrane while main-
taining a transmembrane pressure of 10–12 psi throughout the
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FIG. 2. Productivity and release of various serotypes after PEI transfection in the presence or absence of 500 mM salt.
Fifteen-centimeter plates of HEK293 cells were triple transfected with PEI and DNA mixes containing one of the five different
AAV capsid genes indicated. Five days posttransfection culture media and cells were harvested either with or without
exposure to 0.5 M salt and DNase-resistant vector genome copies (GC) were quantified. Genome copies produced per cell are
represented with the percentage of vector found in the supernatant indicated above each column.
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process. The disposability of the membrane avoided the need
to defoul and sanitize between runs and therefore added to
the reproducibility of the process. The production culture
medium was treated with nuclease (Benzonase) to degrade
contaminating plasmid and cellular DNA, and 500 mM salt
was added before concentration to minimize aggregation of
the vector to both itself (Wright et al., 2005) and to contami-
nating proteins during processing. These two treatments were
subsequently determined to increase recoveries from the
iodixanol gradient (data not shown). During development of
the downstream process and performance of full-scale pilot
runs (Table 1), no significant loss of vector was observed at
any point due to the concentration process.
Iodixanol gradient purification of AAV vectors has been
fully described (Zolotukhin et al., 1999) and the step gradient
used here is adapted from this work. Minor modifications
to the volumes of the gradient layers were made in order
to achieve better resolution of vector from contaminants
(Materials and Methods). Fourteen milliliters of TFF re-
tentate containing concentrated AAV7-eGFP vector from the
production culture medium of one cell stack were loaded
onto a 27-ml iodixanol step gradient and centrifuged for 1 hr
at 350,000g. The gradient was then fractionated from the
bottom of the tube and the fractions (275 ml) were analyzed
for vector content, iodixanol concentration, and vector purity
by qPCR, optical density at 340 nm (Schroder et al., 1997),
and SDS–PAGE, respectively. Representative profiles of one
such gradient are shown in Fig. 3. A linear gradient of io-
dixanol concentration indicated by the decreasing OD340
readings was observed up until fraction 22. After this point
the readings increased (Fig. 3a) and corresponded to a spike
in contaminating protein visualized by SDS–PAGE (Fig. 3b)
and by the naked eye in the form of a thin band present in
the gradient. The OD340 spike was likely due to overlapping
absorbance of protein and iodixanol at this wavelength
and this phenomenon provided us with an accurate and
Table 1. In-Process and Final Yields (Genome Copies) of AAV Vector Pilot Production Runs
TFF1/iodixanol gradient TFF2/buffer exchange
Pilot
runs (no.) Serotype Transgene Feedstock
TFF1
retentate
Iodixanol
fraction pool
Percentage
of feedstock
Final
product
Percentage of
iodixanol pool
Total process
yield (%)
1 AA V9 eGFP 6.411014 3.581014 2.241014 42.15 1.821014 81.34 28.46
8 AA V9 eGFP 1.031015 2.261014a 1.051014 10.20 6.661013 63.57 6.48
9 AA V9 eGFP 3.121014 3.761014 1.631014 52.33 8.381013 51.37 26.88
10 AA V8 eGFP 9.831014 1.221015 4.321014 43.97 2.661014 61.50 27.04
11 AA V8 eGFP 9.241014 1.011015 3.261014 35.29 2.001014 61.27 21.62
12 AA V8 eGFP 1.511015 1.571015 6.061014 40.19 3.671014 60.58 24.35
5 AA V6 eGFP 3.351013 5.691013 6.371012 22.92 2.481012 38.84 7.39
7 AA V6 eGFP 1.011014 1.321014 1.571013 15.58 4.581012 29.12 4.54
Abbreviations: AAV, adeno-associated virus; EGFP, enhanced green fluorescent protein; TFF, tangential flow filtration.
aLoss due to mechanical failure.
FIG. 3. Large-scale iodixanol
gradient-based purification of
rAAV7 vector from concen-
trated production culture su-
pernatants. (a) rAAV7 vector
from cell stack culture me-
dium was concentrated and
separated on iodixanol gradi-
ents and fractions were har-
vested from the bottom of the
tube (fraction 1). Iodixanol
density was monitored at
340 nm and genome copy
numbers for each fraction
were obtained by qPCR. (b)
Equal genome copies (11010)
for each fraction were loaded
onto SDS–polyacrylamide gels
and proteins were visualized
with SYPRO ruby stain. V,
validation lot; M, molecular
weight marker. AAV capsid
proteins VP1, VP2, and VP3
are indicated. The pure AAV
vector peak is indicated by the
boxed area on the SDS–poly-
acrylamide gels.
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reproducible method of detecting the emergence of the
contaminating protein band.
The peak of vector genomes was observed toward the
bottom third of the gradient, between fractions 12 and 22, at
an OD340-extrapolated iodixanol concentration range of 1.31
to 1.23 g/ml (Fig. 3a), just below the start of the contami-
nating cellular protein band (fractions 23 to 28). This peak
coincided with those fractions containing pure vector parti-
cles as judged by the presence of AAV capsids proteins
without contaminating cellular protein (Fig. 3b). Approxi-
mately 50% of the vector genomes consistently comigrated
with the contaminating protein and could not be resolved
despite attempts to do so by using different iodixanol con-
centrations, spin times, salt concentrations, and detergents
(data not shown). Interestingly, despite loading equal
genome copies of each fraction (1010 GC) on the SDS–
polyacrylamide gels, fractions 26, 27, and 28 contained ele-
vated levels of the capsid proteins VP1, VP2, and VP3 (Fig.
3b). This result suggested the presence in these fractions of
either empty capsids or capsid assembly intermediates with
no associated or packaged genome. Separation of empty
capsids from fully infectious capsids by iodixanol gradients
has been demonstrated previously (Potter et al., 2002).
Large-scale pilot production run recoveries and yields
The development work described previously demon-
strated that pure rAAV7 vector could be produced at high
titer from a single cell stack, using a combination of PEI
transfection and iodixanol gradient purification. To properly
characterize the production process and demonstrate repro-
ducibility and applicability to other AAV serotypes, full-
scale pilot production runs were initiated, each using six cell
stacks. The goal for each run was to produce in excess of 1014
GC of final purified vector; the final process employed is
summarized in Fig. 4 and fully detailed in Materials and
Methods. Three runs each of rAAV8-eGFP and rAAV9-eGFP
were performed along with two runs of rAAV6-eGFP. In-
process samples were taken at various stages to assess vector
loss throughout as follows: (1) feedstock samples were taken
after treatment of the culture medium with Benzonase/0.5 M
salt and clarification; (2) retentate samples were taken after
TFF concentration; (3) iodixanol gradient fraction samples
were taken after gradient harvest and fraction pooling; and
(4) final product samples were taken after buffer exchange
and final concentration by a second TFF procedure. The re-
coveries of encapsidated vector genome copies at each of
these stages for the various runs are listed in Table 1.
The mean recovery of rAAV8 and rAAV9 vector in the
feedstock was 9.01014 GC whereas for rAAV6 vectors the
mean recovery was 6.71013 GC. Similar low yields of
rAAV6 vectors were seen in transfections during develop-
ment (Fig. 2) and are also consistently observed in our
standard small-scale AAV production process.
A 125-fold concentration of the feedstock from 10 liters to
85 ml (Table 1: TFF1 retentate) resulted in no loss of vector
except for one instance, in which the loss was due to a me-
chanical failure. In several cases there was an apparent
increase in yield on concentration but this was attributed to
error introduced by extra dilution of the retentate, which was
necessary to overcome inhibition of the qPCR. As was the
case during development runs, there was loss of the vector
during pilot iodixanol purification runs with recoveries be-
tween 35 and 50% of feedstock for AAV8 and AAV9 vectors.
More loss was seen with AAV6 vectors during purification
(80–85% of feedstock) and the reason for this remains un-
clear. Final concentration and buffer exchange led to further
losses although this was most pronounced with AAV6 vec-
tors, possibly because of the lower titer of the starting ma-
terial and therefore a larger fraction of vector was absorbed
to the surfaces of the TFF apparatus. Excluding the run in
which mechanical loss occurred, the average overall process
yield for AAV8 and AAV9 vectors was 2.21014 GC (*26%
of feedstock).
Characterization of large-scale production lots
The vector lots produced in the pilot runs were charac-
terized for capsid protein purity by SDS–PAGE analysis and
for empty particle content by electron microscopy. Only a
few minor bands in addition to the AAV capsid proteins
VP1, VP2, and VP3 could be visualized by SDS–PAGE
analysis in each of the rAAV8 and rAAV9 large-scale pro-
duction lots, and the estimated purity exceeded 90% in all
but a single case (Fig. 5). These results compared favorably
with our standard small-scale process, in which vector pu-
rities exceeding 85% are routinely achieved. Estimates of
empty particle content of the large-scale production lots were
determined by direct observation of negatively stained vec-
tor particles on electron micrographs (Fig. 6). Empty particles
are distinguished on these images by an electron-dense
central region of the capsid in comparison with full particles,
which exclude the negative stain. In comparison with un-
purified preparations, in which the empty-to-full ratio can be
Seed 6 cell stacks HEK 293 cells  
PEI based triple transfection (cis, trans, helper)
Incubate serum –free   37oC,  5 days
Benzonase treat supernatant  
Adjust salt to 500mM  (10L final)
Clarify
TFF 1 (100Kd MWCO) 
Concentrate 125 fold
Clarify
Load to 6x iodixanol step gradients  
1hr   350K x g
Harvest fractions and monitor OD340
Pool pure window
TFF 2 (100Kd MWCO) 
Buffer exchange to final formulation 
Concentrate  (1- 4 x 1013/ mL) 
Day
1
2
6
6
7
7
7
FIG. 4. Summary of the large-scale vector production
process. The major process steps and corresponding timeline
are shown.
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as high as 30:1 (Sommer et al., 2003), the empty particle
content of the pilot production lots ranged from 0.4 to 5%.
An essential quality of any rAAV production lot is the
ability of the vector to deliver and express the gene of interest
in cells. The potency of the rAAV8 and rAAV9 large-scale
production lots relative to vectors produced by our small-
scale process was assessed in vitro by eGFP expression and in
C57BL/6 mouse livers after intravenous injection (Figs. 7 and
8, respectively). By both in vitro and in vivo analysis, all
rAAV8 and rAAV9 vectors manufactured by the new pro-
duction method exhibited equal or higher potency (up to
3.5-fold) when compared with identical vectors produced by
the standard small-scale approach. Although rAAV6 vector
yields were consistently low, the large-scale production lots
still showed 2-fold transduction improvement compared
with rAAV6-eGFP produced at small scale.
Discussion
The demand for rAAV vectors for clinical gene therapy
continues to grow and as the current progress in the field
accelerates, unprecedented quantities of vector for use in
late-stage clinical trials may soon be needed. In parallel, a
growing demand for vector to satisfy the complex require-
ments of preclinical studies is likely to rise as researchers rely
increasingly on large animal data for improved prediction of
clinical outcomes in humans. Several new processes for the
production of rAAV vectors with yields sufficient to fuel
late-stage clinical trials are currently migrating from devel-
opment laboratories to production suites both in industry
and academic institutions (Clement et al., 2009; Virag et al.,
2009; Zhang et al., 2009). However, these processes often
involve time-consuming construction of intermediates such
as hybrid viruses and packaging cell lines and are therefore
ill-suited to the preclinical environment, where several
combinations of transgenes and AAV serotypes must often
be tested under strict timelines. Furthermore, the majority of
preclinical work is performed in academic institutions,
where access to the high-technology equipment used in
many large-scale production processes can be limited. To
support the vector requirements of our preclinical group, we
set out to develop a scaled production process that would
yield sufficient vector for large animal studies while retain-
ing the flexibility and simplicity to rapidly generate any
desired rAAV product in standard AAV laboratories.
The production process we describe is based on PEI triple
transfection, which allows us to maintain some unique
properties of transfection-based production techniques, such
as quick and easy substitutions of various AAV serotype/
transgene combinations. A novel feature of the new process
is that the majority of the vector can be harvested from the
culture medium rather than from the production cells and
thus the bulk of cellular contaminants present in the cell
lysate is avoided. The upstream process is extremely efficient
and yields up to 2105 GC per cell or 11015 GC per lot of
six cell stacks (Fig. 2 and Table 1). The choice of iodixanol
gradient centrifugation for the downstream process was
influenced by our desire to maintain a generic purification
process for all serotypes. The isotonic, relatively inert nature
of iodixanol has proven advantages with regard to main-
taining vector potency (Zolotukhin et al., 1999) and to overall
product safety. By applying concentrated production culture
medium to iodixanol step gradients we were able to obtain
highly pure and potent rAAV vector with acceptable yield in
a single 1-hr centrifugation step. The whole process is rapid
(7 days total; Fig. 4) and cost-effective. The average overall
yields for AAV8 and AAV9 vectors were 2.21014 GC with
an overall process recovery of 26%.
In the current format the production method is partially
serum-free because the cells are grown in 10% fetal bovine
serum before transfection. However, with animal product-
free medium commercially available for 293 cells, the process
should be easily adaptable to be completely serum-free and
meet safety regulations. Similarly, the process is cGMP
compatible because all containers are sealed and manipula-
tions are performed within the confines of a biosafety cabi-
net. Therefore in addition to preclinical studies, the process is
also adaptable for early-stage clinical trials, where vector
demand is low, and for certain applications such as the
treatment of inherited retinal diseases, where low vector
doses are anticipated.
An observation that we made during development of the
upstream process is that rAAV of various serotypes is re-
leased to the supernatant in both calcium phosphate- and
PEI-transfected cultures (Fig. 1). The nature of this release
mechanism is unclear but appears to occur in the absence of
obvious cytopathology. Although the release may be influ-
enced directly by the transfection reagents used, an active
export pathway for AAV virions is a possibility. The type of
transfection technique did not greatly influence the amount
FIG. 5. Purity of large-scale rAAV production lots. Equal
genome copies (11010) of large-scale AAV8 and AAV9
vector preparations were loaded onto SDS–polyacrylamide
gels and proteins were visualized by SYPRO ruby staining.
All protein bands were quantified and the percent purity of
the capsid (VP1, VP2, and VP3 proteins indicated over total
protein) was calculated and indicated below the gel. The
purity of the large-scale lots was compared with a small-
scale CsCl gradient-purified AAV9 vector.
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of vector released to the culture medium, but extending the
incubation period posttransfection led to substantial in-
creases in release. These results contrast with the data of
Okada and colleagues, who found an average of 7-fold more
AAV8 vector in the culture medium versus the cell pellet at
72 hr posttransfection (Okada et al., 2009). These researchers
used calcium phosphate transfection along with an active
gassing system and it is possible that the resulting different
culture conditions contributed to the increase in release at the
earlier time point. Alternatively, in our experience quantifi-
cation of AAV genomes in a complex cell lysate by qPCR can
be prone to nonspecific inhibition of the PCR and it is pos-
sible that the cell lysate amounts were underestimated. In-
terestingly, in experiments not reported here, when the
medium was harvested and replaced on successive days
posttransfection, the recovery of rAAV7 vector in the culture
medium remained constant. This observation suggests that
the incorporation of perfusion culture techniques to the
process may increase upstream yields further still. We chose
to restrict our efforts to adherent HEK293 cultures for rea-
sons of simplicity and convenience, but given the use of PEI
transfection in the production of rAAV in suspension cul-
tures (Durocher et al., 2007; Hildinger et al., 2007), the ad-
aptation of our upstream process to bioreactors appears
feasible. A major advantage of such an approach would be
the ability to use the same upstream process for both pre-
clinical and clinical vector manufacture, which is desirable
from a regulatory standpoint.
Our demonstration that most AAV serotypes can be effi-
ciently harvested from the production culture medium (Fig. 2;
and Vandenberghe et al., 2010) indicates that the new process
will likely be widely applicable to most AAV vectors. How-
ever, for some AAV serotypes modifications will be required.
For example, rAAV2 is mostly retained in the cell (Vanden-
berghe et al., 2010) and release of this serotype to the culture
medium would need to be manipulated, perhaps by a combi-
nation of pH, temperature, and salt treatment (Atkinson et al.,
2005). rAAV6 vectors were not efficiently produced in either
the cells or the culture medium after PEI triple transfection (Fig.
2 and Table 1) and in our hands cannot be reproducibly man-
ufactured at high titer by standard calcium phosphate trans-
fection and cesium chloride gradient purification. These
findings therefore appear to reflect fundamentally different
efficiencies of AAV6 capsid assembly and genome packaging,
or perhaps a lower stability of the AAV6 virion.
Ion-exchange, hydrophobic interaction, and affinity col-
umn chromatography are the methods of choice for capture
of AAV vector from large volumes of culture medium. These
methods must often be developed specifically for each AAV
serotype and therefore for preclinical vector production, a
generic purification method to accommodate multiple sero-
types is a better solution. The TFF concentration/iodixanol
gradient method we have developed is a generic down-
stream approach to rAAV purification and in the studies
presented here produced a vector peak that was pure and
relatively free of empty particles (Figs. 5 and 6). Possible
alternatives to the TFF concentration step we have employed
include precipitation of the vector from the supernatant,
using ammonium sulfate or polyethylene glycol (PEG).
However, at the scale described these procedures would
FIG. 6. Determination of empty-to-full particle ratios in large-scale rAAV8 and rAAV9 production lots. Large-scale rAAV8
and rAAV9 vector preparations were negatively stained with uranyl acetate and examined by transmission electron mi-
croscopy. The pilot run number is indicated on each image. Empty particles can be distinguished on the basis of the electron-
dense center and are indicated by arrows. The ratio of empty to full particles and the percentage of empty particles are shown
below the images. A small-scale AAV8 vector preparation was included in the analysis for comparison.
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FIG. 8. Liver transduction with
rAAV8 and rAAV9 large-scale
production lots. (a) C57BL/6 mice
were injected intravenously with
11011 GC of rAAV8-eGFP and
rAAV9-eGFP vectors produced by
both small- and large-scale pro-
cesses. eGFP fluorescence was
compared in liver sections 9 days
postinjection. (b) eGFP fluores-
cence intensity was quantified di-
rectly from the digital images by
determining the product of
brightness levels and pixels over
background levels. Each column
represents the average intensity
value of liver samples from two
animals.
FIG. 7. Relative transduc-
tion of rAAV8, rAAV9, and
rAAV6 vectors in vitro. (a)
HEK293 cells were infected in
triplicate with rAAV-eGFP
vector lots produced by both
large- and small-scale pro-
cesses at an MOI of 1104
GC/cell in the presence of
adenovirus. GFP transgene ex-
pression was photographed
48 hr postinfection. (b) eGFP
fluorescence intensity was
quantified directly from the
digital images by determin-
ing the product of brightness
levels and pixels over back-
ground levels.
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involve centrifugation of large volumes of supernatant on a
routine basis and this is especially a problem with ammo-
nium sulfate, for which up to 50% saturation is required to
precipitate AAV. Furthermore, it has been our experience
that PEG precipitation can negatively impact the potency of
AAV vectors. TFF, on the other hand, eliminates the need
for centrifugation and the concentration process we de-
scribe can be accomplished in less than 2 hr. A further ad-
vantage of the TFF process is that small proteins will pass
through the filter membrane, which leads to additional
purification.
Flexibility in terms of purification of different serotypes
could not be achieved without cost, because the average
loss of vector on the iodixanol gradient was 57% and
mainly resulted from an inability to completely resolve the
vector from contaminating protein and empty particles
(Table 1). Removal of empty vector particles is a preferred
feature of any rAAV purification protocol because, de-
pending on the production process, this vector-specific
contaminant can be present in vast excess in unpurified
feedstock. A lack of removal of empty particles from the
final product exposes the recipient of the vector to a large
source of AAV antigen that can lead to unwanted immune
responses and toxicity (Wright, 2009). Common column
chromatography-based purification techniques do not dis-
criminate against empty particles, although ion-exchange
methods that are capable of this function have been pub-
lished for AAV1, AAV2, and AAV8 (Qu et al., 2007; Okada
et al., 2009). Like most bulk capture ion-exchange-based
column chromatography processes, these methods for re-
moval of AAV empty capsids must be tailored to a partic-
ular AAV serotype and the shallow elution gradients
employed are likely to present technical challenges during
scale-up. A more robust procedure might involve direct
capture of AAV particles from the production culture me-
dium on ion-exchange or affinity chromatography columns
and subsequent density gradient purification of the con-
centrated column eluate for separation of empty particles.
The integration of such a strategy in place of the TFF con-
centration step described for our process would likely have
the added advantage of decreasing contaminant cellular
protein in the gradient load, increasing resolution of the
iodixanol gradient, and thus ultimately increasing yield of
the vector.
The potency of the rAAV8 and rAAV9 vectors produced
by the new process described was demonstrated in both
in vitro and in vivo transduction assays to be at least
equivalent to if not slightly better than that of identical
vectors produced by our routine small-scale production
method (Figs. 7 and 8). This result might be expected be-
cause iodixanol is less harsh than cesium chloride in terms
of impacting AAV transducing activity (Zolotukhin et al.,
1999) and, in addition, we have been unable to demon-
strate a difference in potency linked to the source of the
rAAV vector (cells vs. culture medium; Vandenberghe
et al., 2010). The delayed harvest featured in the new pro-
cess at 120 hr posttransfection was originally a concern
regarding vector potency but appears to have a negligible,
if any, effect.
In conclusion, the large-scale rAAV vector production
process presented here has been tailored toward the needs of
AAV gene therapy laboratories involved in preclinical trials
and is anticipated to satisfy most requirements of these
studies including the preclinical requirement for flexible
vector manufacture. With some of the modifications sug-
gested, the potential exists to scale up the new method to
supply rAAV vectors for clinical applications while retaining
inherent advantages of the process such as reagent simplic-
ity, process speed, and clearance of vector-specific impuri-
ties.
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